However, since our first-generation CD19R activates T cells through chimeric CD3-z, 3 and as OKT3-mediated ex vivo-expanded genetically modified T cells are typically differentiated effectors with loss of expression of endogenous CD28, modifications to the aAPC platform beyond expression of the CD19 antigen are likely to be needed to achieve robust antigen-dependent T-cell propagation. Two candidate T-cell co-stimulatory molecules for enforced expression on aAPC are 4-1BB ligand (4-1BBL, CD137L) and major histocompatibility class I-related chains (MIC)A. It has previously been demonstrated that an activation event mediated through 4-1BB (CD137) enhances proliferation and cytotoxicity of cytolytic T cells and enforced expression of 4-1BBL on aAPC has been used to help propagate T cells. 2, 6 Natural killer (NK) receptor member D of the lectin-like receptor family (NKG2D)-activating receptor is expressed on the surface of OKT3-stimulated and numerically expanded genetically modified cytolytic T cells. 7 Engagement of NKG2D with MICA, a ligand for NKG2D, delivers a co-stimulatory signal, which can activate T cells for cytotoxicity, cytokine secretion, and proliferation.
In our studies, K562 cells (human erythroleukemic cell line) were selected as a platform for the development of aAPC as they (i) have been used ex vivo to present antigen to, and propagate T cells, (ii) can be cultured in serum-free media and used in compliance with current Good Manufacturing Practice (cGMP), (iii) lack expression of classical human leukocyte antigen molecules, which could lead to non-specific numerical expansion of allo-reactive T cells, and (iv) endogenously express desired T-cell co-stimulatory molecules such as intercellular adhesion molecule-1 (ICAM-1, CD54) and lymphocyte function-associated-antigen-3 (LFA-3, CD58). 6 A panel of K562-derived aAPC (K562 aAPC) was generated by non-viral gene transfer using DNA plasmids to express a combination of the following human complementary DNAs: truncated CD19 antigen, 4-1BBL, and MICA, to generate cell panels with the following four phenotypes:
Expression of the introduced truncated CD19 antigen was similar between these four types of aAPC (61-68%) ( Figure 1 ). Expression of the MICA transgene, fused to a fluorescent reporter gene, on CD19 Figure 1b ) aAPC was similar as measured by expression of green fluorescent protein (GFP) and enhanced GFP (EGFP) (90% and 95%, respectively) and detection using rhNKG2D/Fc (98% and 96%, respectively). Expression of 4-1BBL transgene on
þ aAPC was 79% and 93%, respectively (Figure 1a and c) . Fifty-eight percent of CD19 þ 4-1BBL þ MICA þ aAPC co-express all three transgenes: CD19, 4-1BBL, and MICA (Figure 1a) .
To determine the numerical expansion of CD19R þ T cells using K562 aAPC, CD19R þ T cells initially expanded using OKT3 in cytocidal concentration of hygromycin B, were cocultured with g-irradiated K562 aAPC expressing CD19 and the two co-stimulatory molecules, 4-1BBL and MICA, in the presence of rhIL-2 ( Figure 2a) . We observed that while there was an initial increase in T-cell number over the first 7 days of T-cell and aAPC co-culture, this expansion could not be sustained and the number of T cells declined and could not be re-stimulated with the aAPC. Based on a previous report, 1 we hypothesized that the cultured T cells in the presence of rhIL-2 may be undergoing activation-induced cell death (AICD), despite the presence of 4-1BBL and MICA co-stimulatory molecules. As rhIL-15 can support proliferation and inhibit rhIL-2-mediated AICD of T cells, we demonstrated that replacing rhIL-2 with rhIL-15 resulted in long-term propagation (B130-fold increase) of genetically modified T cells on aAPC over 35 days (Figure 2a ). This numerical expansion further increased to B1630-fold over 35 days of co-culture when exogenous rhIL-15 was added in addition to rhIL-2 ( Figure 2a) . We confirmed the beneficial effect of using both rhIL-15 and rhIL-2 on T-cell propagation by comparing the numerical expansion of CD19R þ T cells on the panel of four K562 aAPC, which express CD19, but differ in expression of T-cell costimulatory molecules (Figure 2b ). The best 35-day T-cell propagation was achieved using CD19 þ 4-1BBL þ MICA þ aAPC (B3620-fold increase in numerical expansion), followed by co-culture of T cells with K562 aAPC co-expressing CD19 and 4-1BBL (B674-fold numerical expansion). There was numerical expansion of T cells on CD19 þ MICA þ aAPC, but this peaked at B49-fold after 21 days. T cells propagated on CD19 þ aAPC initially numerically expanded, but this could not be maintained despite the presence of rhIL-2 and rhIL-15. Thus, IL-15 is necessary, but not sufficient for propagation of T cells activated Letters to the Editor by chimeric CD3-z by CD19 on K562 aAPC. However, in the presence of IL-15 (and IL-2), co-stimulation through 4-1BBL, and enhanced by MICA, on K562 aAPC is sufficient to maintain long-term proliferation of CD19R þ T cells. The relative immunostimulatory versus immunosuppressive effects of NKG2D signaling of T cells is complex. We were able to demonstrate a role for MICA in activating genetically modified T cells for long-term sustained propagation only when coexpressed with 4-1BBL on CD19 þ aAPC ( Figure 2b ). However, the presence of MICA along with CD19 did result in a modest long-term propagation of CD19R þ T cells and prevention of collapse of the T-cell numbers, as occurred when the genetically modified T cells were co-cultured with CD19 þ aAPC.
It was predicted that sustained propagation on CD19R þ aAPC of a population of CD19R þ T cells, starting with a heterogeneous expression of CD19R transgene, should result in an outgrowth of T cells with increased expression of the CD19R. Using flow cytometry to detect cell-surface expression of the Fcregion of the CD19R, we demonstrated that the percentage of CD19R þ T cells increased from 3270.5% (mean7s.d. for three separate expansions) before co-culture compared with 8372.4% (mean7s.d. for three separate expansions) after five 7-day cycles of stimulation with g-irradiated CD19
þ 4-1BBL þ MICA þ aAPC (Po0.01) (Figure 2c ). Just as there was an increase in the percentage of genetically modified T cells expressing the CD19R, so too there was an increase in the density of CD19R on each CD19R
þ T cell as measured by the median fluorescent intensity (MFI) (before aAPC co-culture MFI ¼ 19; after aAPC co-culture MFI ¼ 32). The increased CD19R expression was confirmed by Western blot using monoclonal antibody specific for CD3-z chain (Figure 2d ). The calculated density of the CD19R protein band before and after long-term co-culture on K562 aAPC was 129 OD units and 1211 OD units, respectively, whereas the density of the endogenous CD3-z before and after long-term co-culture was approximately the same (2197 OD units and 2294 OD units, respectively).
We investigated whether, in addition to being a superior substrate for T-cell propagation, the CD19 þ 4-1BBL þ aAPC and CD19 þ MICA þ aAPC (Po0.01 and Po0.05, for Daudi and SUP-B15 targets, respectively). Control for specificity for the killing was demonstrated by the lack of lysis of CD19 neg K562 target cells. As these K562 targets are sensitive to NK-mediated lysis, these cells serve as a dual control and also demonstrate that the co-culture conditions using K562 aAPC did not result in an outgrowth of T cells with detectable endogenous NK activity. Thus, the CD19 þ 4-1BBL þ MICA þ aAPC were not only the most efficient cells for propagating CD19R
cells with improved cytolytic activity, as assessed by 4-h chromium release assay (CRA). It was observed that genetically modified T cells numerically expanded for 35 days on
þ T cells, but the co-culture conditions using these aAPC further selected for genetically modified T cells with a significantly superior cytolytic activity against CD19 þ lymphoma and leukemia cells. A recent study has demonstrated that K562 aAPC expressing 4-1BBL could activate, via the endogenous ab-TCR, human and mouse T cells for numerical expansion ex vivo. 6 Our data extend these observations by demonstrating that expression of 4-1BBL along with CD19 on g-irradiated aAPC results in (i) sustained propagation of CD19R þ T cells and (ii) improved numerical expansion and cytolytic activity when 4-1BBL is coexpressed with MICA on CD19 þ aAPC. Furthermore, since K562 cells do not express CD80 or CD86, we show that the propagation of genetically modified T cells can be achieved independent of co-stimulation through endogenous CD28. This is in contrast to an earlier study which demonstrated that for T cells expressing a CD19R (which signals through chimeric CD3-z), rhlL-15 was necessary, but insufficient for long-term propagation of these genetically modified human CD19-specific cytolytic T cells on CD19 þ aAPC derived from murine 3T3 cells, and sustained ex vivo T-cell proliferation was achieved only when human CD80 was co-expressed on these aAPC with Letters to the Editor the addition of exogenous rhIL-15. 1 In addition, a recent report has demonstrated that CD19R þ T cells (expressing a CD19R signaling through chimeric CD3-z) only proliferate and propagate when adequate co-stimulation is provided, such as in response to autologous and allogeneic (CD19 þ ) LCL, but not CD19 þ tumor lines. 8 When these results are taken together, it appears that for differentiated effector T cells expressing a firstgeneration CD19R (capable of signaling through chimeric CD3-z) to propagate on CD19 þ aAPC (derived from K562 cells, 3T3 cells, or LCL), there must be a co-stimulation event, mediated for example, through the receptor/ligand pairs 4-1BB/4-1BBL or CD28/CD80; and proliferation is typically sustained by the addition of exogenous rhIL-15. The impact of these ex vivo observations on persistence of infused CD19R þ T cells in the clinical setting remains to be determined. In our current trial, the CD19R þ T cells are adoptively transferred with exogenous rhIL-2 after lymphodepleting/immunosuppressive chemotherapy, which should result in a rise in endogenous IL-15 levels. In this environment, we will assess whether the infused CD19R þ T cells can be activated by autologous malignant and nonmalignant B cells for sustained proliferation. In summary, we have generated aAPC from K562 cells by enforcing cell-surface expression of truncated CD19 antigen along with two T-cell co-stimulatory molecules and evaluated their potential as a new platform for CD19R-mediated ex vivo propagation of genetically modified CD19-specific cytolytic T cells expressing a first-generation CD19R. In aggregate, these data provide the justification for manufacturing the K562 aAPC in compliance with cGMP to use the CD19
The efficacy of the CD19R þ T cells numerically expanded on K562 aAPC will be determined by adoptive immunotherapy clinical trials.
Figure 2
Long-term numerical expansion of genetically modified CD19-specific cytolytic T cells on (a) CD19 þ 4-1BBL þ MICA þ aAPC and (b) The panel of four K562 aAPC. After g-irradiation (100 Gy), aAPC were added at 1:2 ratio to genetically modified T cells every 7 days (indicated by downward arrow). RhIL-2 (25 U/ml) and/or rhIL-15 (10 ng/ml) were added to culture media on a Monday-Wednesday-Friday schedule, beginning on the first day of co-culture. On day 3 of the co-culture, hygromycin B was added at a cytocidal concentration of 0.2 mg/ml (active drug). The concentration of T cells was maintained at 0.5 Â 10 6 to 10 6 /ml throughout the co-culture periods. The viable CD19R þ T cells were enumerated every 7 days based on exclusion with trypan blue and flow cytometry analysis (staining with propidium iodine (PI) and CD8-specific monoclonal antibody). (c) Expression of introduced CD19R (measured by binding of polyclonal Fc-specific antibody) by genetically modified T cells using flow cytometry 4 (result shown is from one example of three separate experiments) and confirmed by (d) Western blot probed with anti-CD3-z under reducing conditions 3 (I) before and (II) after co-culture with CD19 þ 4-1BBL þ MICA þ aAPC (and rhIL-15 and rhIL-2) for 35 days. (e) Genetically modified CD19-specific cytolytic T cells expanded on the panel of three K562 aAPC (CD19 In the search for new treatment modalities necessary to eradicate minimal residual disease cells in acute myeloid leukemia (AML), immunotherapy provides an attractive option. AML blasts have proven to be able to differentiate into dendritic cell (DC)-like leukemic antigen-presenting cells (APC) under serum-free, good clinical practise, conditions with the use of cytokines or calcium ionophores (CI), thereby providing the unique opportunity to generate APC harbouring the full range of potential, still unidentified tumor antigens. 1 In in vitro assays, cultured AML-DC have proven to fulfil all criteria necessary to elicit potent T-cell responses in vivo, such as migration towards lymph node associated chemokines, and induction of leukemiaspecific activation of cytotoxic T cells. [1] [2] [3] Here, we report the development of a predictive model for leukemic DC differentiation established in a large cohort of 154 patients. AML blast characteristics were studied in order to develop a model by which the outcome of an AML-DC culture can be established before culture, thus enabling selection of patients eligible for AML-DC vaccination protocols.
After informed consent, peripheral blood and bone marrow mononuclear cells of patients (n ¼ 154) diagnosed with AML in the period between 1999 and 2005 were cultured in presence of cytokines (n ¼ 147) and/or CI (n ¼ 108) as published previously (patient characteristics are shown in Table 1 ). 1 Briefly, fresh or thawed mononuclear cells were cultured in either Rosewell Park Memorial Institute 1640; 20% fetal calf serum or CellGro serum-free medium (CG); 100 U/ml penicillin and 100 mg/ml streptomycin. Differentiation towards DC was induced by the addition of a combination of cytokines: granulocyte-macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF-a), interleukin (IL)-3, stem cell factor (SCF), Flt3-L and IL-4 or CI A23187 and IL-4. Medium exchange with fresh medium supplemented with GM-CSF, TNF-a and IL-4, was routinely performed in case of an overgrown culture or medium exhaustion. After 2 and 14 days of culture, in presence of either CI or cytokines, respectively, cells were harvested. Prior and subsequent to culture phenotypic analysis of the following markers was performed by flowcytometry: CD34, CD14, CD45, CD40, CD54, CD80, CD86, CD83, CD1a, HLA-DR and CD120a as described previously. 1 Results were calculated as percentage positive cells as compared to the appropriate isotype control. Analysis of the results was carried out using CellQuest software (Becton Dickinson, San Jose, CA, USA). Apoptotic and necrotic cells, identified by syto-16 and 7-amino-actinomycin staining, as described previously, were excluded from the analysis. 1 A definition for AML-DC was formulated according
